The Expected Impact of HPV Vaccination on the Accuracy of Cervical Cancer Screening: The Need for a Paradigm Change

This publication has 39 references indexed in Scilit:

• Optimization of primary and secondary cervical cancer prevention strategies in an era of cervical cancer vaccination: A multi-regional health economic analysis
  Vaccine, 2008
• Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial
  The Lancet, 2007
• Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials
  The Lancet, 2007
• High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up
  British Journal of Cancer, 2006
• Sustained efficacy up to 4·5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial
  The Lancet, 2006
• Evaluating Human Papillomavirus Vaccination Programs
  Emerging Infectious Diseases, 2004
• Projected Clinical Benefits and Cost-effectiveness of a Human Papillomavirus 16/18 Vaccine
  JNCI Journal of the National Cancer Institute, 2004
• Potential Health and Economic Impact of Adding a Human Papillomavirus Vaccine to Screening Programs
  JAMA, 2003
• Human papillomavirus is a necessary cause of invasive cervical cancer worldwide
  The Journal of Pathology, 1999
• Epidemiologic Evidence and Human Papillomavirus Infection as a Necessary Cause of Cervical Cancer
  JNCI Journal of the National Cancer Institute, 1999